Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing pembrolizumab to chemotherapy in advanced melanoma has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-28